NCT05178836Unknown2 期
An Open-label, Single-arm, and Multicenter Phase Ⅱ Study to Evaluate the Efficacay and Safety of F520 Combined With F007 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 62
- 主要终点
- 1. Objective response rate (ORR)
研究概览
简要总结
This is an open-label, single-arm, and multicenter phase Ⅱ study designed to evaluate the efficacy and safety of F520 (PD-1) combined with F007(rituximab biosimilar) in patients with Relapsed/Refractory diffuse large B-cell lymphoma. About 62 patients with relapsed/refractory DLBCL plan to be enrolled in about 8 study sites of the study.
Primary objective:
The purpose is to evaluate the objective response rate of F520 combined with F007 in Relapsed/Refractory diffuse large B-cell lymphoma.
Secondary objective:
The purpose is to compare the safety of F520 combined with F007 in Relapsed/Refractory diffuse large B-cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged ≥18 and ≤80 years old.
- •CD20-positive relapsed/refractory DLBCL (≥ 2 prior lines of therapy )
- •Recurrence: Relapse occurred more than 6 months after the end of treatment. At least one regimen contains Rituximab.
- •Refractory: Relapse within 6 months after the end of treatment or fail to reach PR after 2 treatment cycles and fail to reach CR after 4 treatment cycles. At least one regimen contains Rituximab.
- •Recurrence after second-line treatment sequential autologous hematopoietic stem cell transplantation.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •More than 3 months life expectancy.
- •Those who agree to provide archived tumor tissue samples or fresh tissue samples
- •Biopsy confirmed CD20-positive after the last treatment. Recurrence more than 1 year needs to undergo tissue biopsy to confirm the pathological diagnosis.
- •Adequate cardiac function (LVEF≥50%).
- •At least one measurable lesion:
- •For intranodal lesions, the long diameter should be >1.5cm; for extranodal lesions, the long diameter should be >1.0cm.
- •Neutrophil count (NEUT) ≥1.5×109/L and platelet count (PLT) ≥75*109/L and hemoglobin ≥75g/L, total bilirubin level (TBIL) ≤1.5×upper limit of normal (ULN), aspartic acid Aminotransferase (AST), alanine aminotransferase (ALT)≤2.5×ULN, creatinine level (Cr)≤1.5×ULN. Patients with liver metastases (TBIL≤3×ULN, ALT/AST≤5×ULN).
- •Signed an informed consent form which was approved by the institutional review board of the respective medical center.
排除标准
- •Primary mediastinal (thymic) large B-cell lymphoma.
- •Transformed lymphoma.
- •DLBCL invaded by special parts, such as central nervous system (CNS), testis, breast, ovary, etc.
- •High-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangement.
- •History of other malignancies (except for basal/squamous cell carcinoma of the skin, in-situ carcinoma of the cervix or breast, superficial bladder cancer, lung carcinoma in situ that have been cured for more than 5 years).
- •Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV-DNA titer higher than 2000 IU/mL or 1000 copies) or hepatitis C virus (HCV). Treponema pallidum (TP) antibody positive.
- •Received systemic anticancer therapy include radiation, targeted therapy, or any other anticancer therapy within 3weeks or 5 half-lives before the first administration.
- •Participation in another clinical trial in the past 4 months.
- •Received allogeneic stem cell transplantation.
- •Previous treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibody or other medications that stimulates or collaboratively inhibits T cell receptors or CAR-T.
- •Usage of immunosuppressive agents, systemic or local hormone therapy within 14 days before the first administration to achieve the purpose of immunosuppression (the daily dose is equivalent to systemic corticosteroids with prednisone> 10 mg).
- •Vaccination with an attenuated live vaccine within 4 weeks before the first administration.
- •Suffered from interstitial pneumonia in the past 6 months.
- •Severe cardiovascular disease (New York Heart Association functional class III or IV, myocardial infarction or unstable arrhythmia or unstable angina in the last 6 months, severe cardiac insufficiency, rogressive multifocal leukoencephalopathy)
- •Uncontrolled hypertension (SBP≥180mmHg and/or DBP≥100mmHg).
- •Active autoimmune diseases, including but not limited to systemic lupus erythematosus, ankylosing spondylitis, etc.
- •Severe mental illness.
- •Known hypersensitivity to any of the study drugs or its ingredients.
- •Pregnant or lactating women.
- •The researcher believes that it is not suitable for enrollment.
研究组 & 干预措施
F520+F007
Experimental
Treatment period：
F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 14-day cycle for 8 cycles.
F520 (200mg) administered intravenously (IV) on Day 2 of each 14-day cycle for cycle 1.
F520 (200mg) administered intravenously (IV) on Day 1 of each 14-day cycle for cycle 2 to 8.
Maintenance period：
F007 (375 mg/m2) administered intravenously (IV) on Day 1 of each 56-day cycle for 10 cycles.
F520 (200mg) administered intravenously (IV) on Day 1/15/29/43 of each 56-day cycle for 10 cycles.
干预措施: F520+F007 (Drug)
结局指标
主要结局
1. Objective response rate (ORR)
时间窗: 16 weeks
To evaluate the objective response rate in patients with relapsed or refractory DLBCL.
次要结局
- 1. Complete response rate (CRR)(16 weeks)
- 2. Progression-free survival (PFS)(2 years)
- 3. Duration of remission (DOR)(2 years)
- 4. Time to progression (TTP)(2 years)
- 5. Overall survival (OS)(2 years)
研究者
相似试验
尚未招募
2 期
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)PD-1Non-small Cell Lung CancerNSCLCNCT05741021Shandong New Time Pharmaceutical Co., LTD84
招募中
2 期
Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct AdenocarcinomaBile Duct AdenocarcinomaNCT06092645Zhejiang Cancer Hospital48
Unknown
2 期
HMPL-453 in Advanced Malignant MesotheliomaAdvanced Malignant MesotheliomaNCT04290325Hutchison Medipharma Limited27
招募中
2 期
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell NeoplasmsB-Cell NeoplasmNCT06508931Miltenyi Biomedicine GmbH31
终止
2 期
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric CancerNCT06206278LianBio LLC6